Posted by Michael Wonder on 01 Jun 2022
Health Canada authorises Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema
1 June 2022 - Vabysmo (faricimab injection) is the first bispecific antibody that acts by neutralising both VEGF-A and Ang-2 proteins, a dual mode of action.
Roche Canada is pleased to announce today that Health Canada authorized Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema, two of the leading causes of vision loss among Canadians.
